Elite Trades From Anywhere

$100 Off Your First Year

Claim Now
Last Close
0.5221
Jun 30 • 04:00PM ET Dollar change+0.0801 Percentage change(18.12%)
Jun 29, 11:02 AMTakeAim CLL trial site activation and dosing update propel CRIS surge
Index
-
Market Cap
20.35M
Enterprise Value
6.69M
Income
-21.16M
Sales
7.06M
Book/sh
0.32
Cash/sh
0.38
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
24
IPO
Aug 01, 2000
P/E
-
Forward P/E
-
PEG
-
P/S
2.88
P/B
1.64
P/C
1.36
P/FCF
-
EV/EBITDA
-
EV/Sales
0.95
Quick Ratio
1.11
Current Ratio
1.11
Debt/Eq
0.11
LT Debt/Eq
0.01
Option/Short
No / Yes
EPS (ttm)
-1.19
EPS next Y
-1.01
EPS next Q
-0.41
EPS this Y
-172.41%
EPS next Y
35.76%
EPS next 5Y
-27.42%
EPS past 3/5Y
63.79% 45.78%
Sales past 3/5Y
-2.42% -2.71%
EPS Y/Y TTM
80.84%
Sales Y/Y TTM
-36.95%
EPS Q/Q
0.01%
Sales Q/Q
-100.00%
Insider Own
18.30%
Insider Trans
0.14%
Inst Own
40.45%
Inst Trans
29.28%
ROA
-61.34%
ROE
-693.93%
ROIC
-165.16%
Gross Margin
97.89%
Oper. Margin
-485.12%
Profit Margin
-299.66%
SMA20
24.07%
SMA50
4.60%
SMA200
-46.87%
Trades
Shs Outstand
39.98M
Shs Float
31.84M
52W High
2.48 -78.97%
52W Low
0.18 189.09%
Volatility
55.73% 21.85%
ATR (14)
0.08
RSI (14)
57.31
Beta
3.10
Rel Volume
4.24
Avg Volume
2.93M
Volume
12,429,837
Perf Week
44.35%
Perf Month
-7.92%
Perf Quarter
1.89%
Perf Half Y
-50.75%
Perf YTD
-47.11%
Perf Year
-77.50%
Perf 3Y
-96.85%
Perf 5Y
-99.68%
Perf 10Y
-99.67%
Prev Close
0.44
Price
0.52
Change
18.12%
Date Action Analyst Rating Change Price Target Change
May-19-25Resumed H.C. Wainwright Buy $17
Nov-17-23Initiated Truist Buy $26
Apr-04-22Downgrade Raymond James Outperform → Mkt Perform
Oct-13-21Initiated Raymond James Outperform $15
Mar-25-21Initiated B. Riley Securities Buy $19
Jul-29-20Initiated Laidlaw Buy $5
Jul-17-20Initiated Cantor Fitzgerald Overweight $4
Oct-24-17Initiated Guggenheim Buy $7
Mar-02-16Initiated Sun Trust Rbsn Humphrey Buy $3
Nov-09-15Reiterated ROTH Capital Buy $6 → $5
Jun-29-26 06:37AM
Jun-26-26 09:42AM
May-13-26 08:30AM
01:02AM
May-12-26 04:10PM
04:00PM Loading…
04:00PM
May-05-26 05:11PM
Mar-19-26 11:02PM
08:12PM
04:11PM
04:00PM
Mar-12-26 04:27PM
Jan-09-26 08:00AM
Jan-07-26 08:45AM
Dec-09-25 08:00AM
09:26AM Loading…
Nov-14-25 09:26AM
Nov-07-25 12:02AM
Nov-06-25 05:10PM
04:08PM
04:00PM
Oct-30-25 04:00PM
Oct-03-25 04:00PM
Sep-02-25 10:43AM
Aug-06-25 11:00AM
Aug-05-25 09:10AM
08:08AM
08:00AM
Aug-04-25 10:13AM
Jul-29-25 08:30AM
Jul-02-25 08:32AM
03:07AM Loading…
May-07-25 03:07AM
May-06-25 06:16PM
09:05AM
08:13AM
08:00AM
May-05-25 10:26AM
May-01-25 10:01AM
Apr-29-25 08:00AM
Apr-12-25 11:00AM
Apr-02-25 04:05PM
Apr-01-25 03:01AM
01:42AM
Mar-31-25 09:59AM
08:16AM
08:00AM
Mar-28-25 04:07PM
Dec-10-24 08:00AM
Nov-15-24 02:37AM
02:07AM
Nov-14-24 09:10AM
08:09AM
08:00AM
Nov-13-24 07:31AM
Nov-07-24 08:00AM
Nov-02-24 11:20AM
Oct-29-24 06:04AM
Oct-09-24 03:42PM
Sep-23-24 08:30AM
Sep-17-24 07:30AM
Sep-04-24 08:00AM
Aug-01-24 09:10AM
08:07AM
08:00AM
Jul-25-24 08:00AM
Jul-10-24 07:30AM
Jul-09-24 12:00PM
Jul-08-24 07:30AM
May-14-24 04:00PM
May-10-24 08:00AM
May-08-24 11:39AM
May-07-24 12:53PM
08:08AM
08:00AM
Apr-30-24 08:00AM
Apr-05-24 08:43AM
07:30AM
Apr-04-24 07:30AM
Feb-09-24 10:10AM
Feb-08-24 08:11AM
08:00AM
Feb-01-24 08:00AM
Jan-05-24 08:00AM
Dec-12-23 08:00AM
Dec-11-23 08:00AM
Dec-06-23 08:00AM
Dec-05-23 08:00AM
Nov-03-23 10:26AM
06:03AM
Nov-02-23 08:19AM
08:00AM
Oct-30-23 10:00AM
Oct-26-23 08:30AM
Oct-06-23 08:56AM
Sep-22-23 03:15AM
Sep-12-23 08:00AM
Sep-06-23 08:13AM
Aug-05-23 05:57AM
Aug-03-23 05:45PM
04:43PM
04:01PM
Curis, Inc. engages in the development and commercialization of drug candidates for the treatment of human cancers. Its pipeline includes CUDC-907, CA-4948, CA-170 and CA-327. The CUDC-907 pipeline is an orally available small molecule inhibitor of HDAC and PI3K enzymes. The CA-170 pipeline is an also an orally-available small molecule antagonist of PD-L1 and VISTA immune checkpoints. The company was founded on February 14, 2000 and is headquartered in Lexington, MA.
PresidentMr. James E. Dentzer
Chief Development OfficerDr. Jonathan B. Zung Ph.D.
Vice President of Technology Management & Intellectual PropertyMr. Mark W. Noel
VP & General CounselMs. Nancy Soohoo
Senior Director of Human ResourcesMs. Rachel Blasbalg
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
KAITIN KENNETH IDirectorMar 31 '26Buy0.5510,0005,48711,407Apr 01 07:51 AM